Retrospective data analysis of twenty work-related injured workers who received autologous tenocyte injection for chronic resistant lateral epicondylitis between 2011 to 2018. A clinical and economic perspective

Background: Lateral epicondylitis or tendinopathy is the most common cause of lateral elbow pain, and chronic resistant lateral epicondylitis (CRLE) is a problem for many workers. Among the non-surgical treatments, autologous tenocyte injection (ATI) is relatively new and may provide faster recovery. Objectives- To assess WorkCover patients with CRLE who have undergone ATI rather than surgical intervention. To analyse their recovery period, pain score, functional capacity and changes in MRI findings. And to estimate any economic advantage of ATI over surgery. Methodology: A retrospective data analysis was performed on 20 patients with work-related CRLE who received ATI. It evaluated their ability to return to work and their quality of life. Using Australian Medical Association and Medicare Benefits Schedule item numbers, an estimated cost comparison was made between non-operative ATI and the current surgical treatment. Results: Of 20 workers (11 M/ 9 F) (mean age 47.1 years), at the time of ATI, 11 (55%) had limited work capacity, and 9 (45%) were absent from work. 80 % of workers with CRLE for more than 12 months returned to full duty (mean 6.6 months) following ATI. Estimated treatment cost and return to full duty duration were less with ATI than with surgery. Conclusion: Overall treatment success with ATI is promising, with earlier return to work, improved functionality and cost-effectiveness compared to surgery.